OPKO’s GeneDx Presenting on a Number of Topics at the 2016 ACMG Annual Clinical Genetics Meeting

March 02, 2016 8:30am EST

Download as PDF

MIAMI--(BUSINESS WIRE)--

OPKO Health, Inc. announced today that its GeneDx subsidiary and

business unit has been selected to give 11 platform talks and 18 poster

presentations on a range of genetics-related topics at the 2016 American

College of Medical Genetics and Genomics (ACMG) Annual Meeting. These

presentations support GeneDx’s position as an industry leader in the

wider genomics industry.

Marc Grodman MD, CEO of BioReference/GeneDX states, “We are honored to

have such a large number of presentations accepted at this year’s ACMG

meeting and believe the depth and scope of our contributions demonstrate

not only our commitment in expanding the scope of our genomic testing

but also a meaningful contribution to enrich the scientific community at

large.”

This year’s presentations cover a range of topics ranging from inherited

cancer testing to whole exome sequencing. Some of GeneDx’s featured

presentations at the meeting include

GeneDx’s experience from the first 100 XomeDx Xpress cases

performed for patients in critical care including diagnostic yield and

how the results impacted medical management;

The potential use of Whole Exome Sequencing for fetal anomalies and

fetal demise;

The detection of mosaic variants in genes causing germline

neurodevelopmental disorders, such as epilepsy;

Multiple talks describing genes that have recently been associated

with neurodevelopmental delay, either as a new gene-disease

association or as an expansion of a previously described clinical

phenotype.

For a complete list of GeneDx’s platform presentations and posters,

please visit the GeneDx website http://www.genedx.com/acmg2016/

or stop by and visit booth #413 at the 2016 ACMG conference to learn

more.

Over the last several years, GeneDx has been striving to better

understand the genetic causes of autism and intellectual disability

through research and its robust Whole Exome Sequencing program, perhaps

best demonstrated by several of the company’s presentations at this

year’s ACMG annual meeting. Based on this increased understanding and

knowledge, GeneDx is proud to announce the launch of its Autism/Intellectual

Disability (ID) Xpanded Panel . This is a dynamic testing panel

analyzing approximately 2,000 genes that have been associated with

autism, intellectual disability and/or developmental delay.

To learn more about GeneDx’s complete list of testing options, please

visit www.genedx.com

or email genedx@genedx.com .

About OPKO Health, Inc.

OPKO Health, Inc. is a diversified healthcare company that seeks to

establish industry-leading positions in large, rapidly growing markets.

Our diagnostics business includes Bio-Reference Laboratories, the

nation's third-largest clinical laboratory with a core genetic testing

business and a 420-person sales force to drive growth and leverage new

products, including the 4Kscore® prostate cancer test and the Claros®1

in-office immunoassay platform. Our pharmaceutical business features

Rayaldee™, a treatment for SHPT in stage 3-4 CKD patients with vitamin D

insufficiency (March 29, 2016 PDUFA date) and VARUBI™ for

chemotherapy-induced nausea and vomiting (oral formulation launched by

partner Tesaro, IV formulation in Phase 3). Our biologics business

includes hGH-CTP, a once-weekly human growth hormone injection (in Phase

3 and partnered with Pfizer), and a long-acting Factor VIIa drug for

hemophilia (entering Phase 2a). We also have production and distribution

assets worldwide, multiple strategic investments and an active business

development strategy. More information is available at www.opko.com .

About GeneDx

GeneDx is a world leader in Genomics with an acknowledged expertise

in rare and ultra rare genetic disorders, as well as one of the broadest

menus of sequencing services available among commercial laboratories.

GeneDx provides testing to patients and their families in more than

55 countries. To learn more, please visit www.genedx.com .

View source version on businesswire.com: http://www.businesswire.com/news/home/20160302005766/en/

OPKO Health, Inc .

Carly Erickson, 202-600-4558

or

Tara

Mackay, 305-575-4100

Investor Relations

or

Media

Rooney

& Associates

Terry Rooney, 212-223-0689

or

Marion

Janic, 212-223-4017

Source: OPKO Health, Inc.

Released March 2, 2016

email Email Alerts

location_city Company Profile

contact_page Contacts

rss_feed RSS News Feed

account_tree Sitemap